PSTV NASDAQ
Plus Therapeutics, Inc.
1W: -0.3%
1M: -20.1%
3M: +1960.1%
YTD: +950.5%
1Y: +1288.1%
3Y: +35.0%
5Y: -82.1%
$5.90
+0.07 (+1.20%)
Weekly Expected Move ±13.5%
$4
$5
$5
$6
$7
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
0
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$14.1M
52W Range2.9-23.5
Volume141,563
Avg Volume323,484
Beta1.40
Dividend—
Analyst Ratings
Company Info
CEOMarc H. Hedrick
Employees21
SectorHealthcare
IndustryBiotechnology
IPO Date2001-07-11
Websiteplustherapeutics.com
4200 Marathon Boulevard
Austin, TX 78756
US
Austin, TX 78756
US
737 255 7194
About Plus Therapeutics, Inc.
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Latest News
Plus Therapeutics (PSTV) Reports Q1 Loss, Tops Revenue Estimates
Plus Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update on REYOBIQ™ Clinical Program and CNSide® Commercial Rollout
Catalyst Pharmaceutical (CPRX) Surpasses Q1 Earnings and Revenue Estimates
OmniAb, Inc. (OABI) Reports Q1 Loss, Tops Revenue Estimates
Plus Therapeutics Receives Medicare Enrollment Approval for CNSide Diagnostic
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| van Es-Johansson An | A-Award | 3,686 | $5.76 | 2026-05-14 |
| van Es-Johansson An | A-Award | 3,686 | — | 2026-05-14 |
| Hawkins Richard J | A-Award | 3,686 | — | 2026-05-14 |
| Hawkins Richard J | A-Award | 3,686 | $5.76 | 2026-05-14 |
| Guse Kyle | A-Award | 3,686 | — | 2026-05-14 |